Panobinostat, sold as Farydak, is a hydroxamic acid compound that works as a non-selective histone deacetylase inhibitor, blocking multiple HDAC enzymes at once. This disrupts the normal packaging of DNA inside cancer cells and pushes them toward programmed cell death through several overlapping pathways. It is used mainly to treat multiple myeloma in adults who have already received at least two earlier lines of treatment, given in combination with bortezomib and dexamethasone. The United States approved it in February 2015 and the European Union followed in August 2015, both under an orphan drug designation reflecting its development for a relatively rare cancer. The medication was withdrawn from the United States market in March 2022.
Facts
Drug ClassHistone deacetylase (HDAC) inhibitor 4 Approved UseMultiple myeloma, in combination with bortezomib and dexamethasone, in patients who have received at least two prior standard therapies 4 First Approved / Isolated Year Significant RiskBoxed warning: severe diarrhea and severe and fatal cardiac events, arrhythmias, and electrocardiographic changes 4 Mechanism of Action Classification
Approval Status ATC ClassSourced to the subject's own accountL: Antineoplastic and Immunomodulating Agents 2 Route of Administration Connections
Sources
1. Panobinostat (Wikipedia)
Lead section, approval-status statementQuote, Lead section, approval-status statement
Panobinostat was approved for medical use in the United States in February 2015, and in the European Union in August 2015.
2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code LQuote, First-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
3. Panobinostat (Wikipedia)
WikipediaInfobox drug, routes_of_administrationQuote, Infobox drug, routes_of_administration
By mouth
4. FDA Approves Panobinostat Combination for the Treatment of Multiple Myeloma (The ASCO Post, 2015)
Opening section, drug class sentence
Panobinostat is the first histone deacetylase (HDAC) inhibitor approved to treat multiple myeloma.
Opening section, mechanism category (HDAC inhibitor)
Panobinostat is the first histone deacetylase (HDAC) inhibitor approved to treat multiple myeloma.
Opening paragraph, combination regimen
in combination with bortezomib (Velcade) and dexamethasone
Side Effects section, boxed warning toxicities
severe diarrhea and severe and fatal cardiac events, arrhythmias, and electrocardiographic changes
View the Source5. Drugs.com: Farydak (panobinostat) FDA Approval History
FDA Approval HistoryQuote, FDA Approval History
Farydak (panobinostat) was first approved by the FDA on February 23, 2015
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.